Ther Adv Vaccines Immunother
May 2021
The objective of this manuscript was to review and evaluate the efficacy and safety data of Dengvaxia for the treatment of severe secondary dengue infection. Dengvaxia is the brand name for chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV). A literature search through PubMed was conducted using the keywords 'dengue vaccine', 'Dengvaxia', 'efficacy' or 'safety'.
View Article and Find Full Text PDF